A prospective, multicentre, open label trial to find the efficacy of rituximab for management of thrombotic thrombocytopenic purpura, relapsed or refractory to therapeutic plasma exchange.
Phase of Trial: Phase II
Latest Information Update: 02 Apr 2015
At a glance
- Drugs Rituximab (Primary)
- Indications Thrombotic thrombocytopenic purpura
- Focus Adverse reactions; Therapeutic Use
- 02 Apr 2015 New trial record